Cumazid, a new prophylactic immunotherapy preparation, has been created based on the total glycoside fraction isolated from Cucumaria japonica sea cucumber species. The acute and chronic toxicity of the preparation has been characterized according to the pharmacopoeieal requirements. With respect to the acute toxicity upon intragastric administration, cumazid belongs to class IV (weakly dangerous) drugs. In 3-month chronic tests, cumazid administered in doses within 1 - 100 microg/kg did not produce any significant toxic action on laboratory animals.